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Abstract Retention of intracellular secreted APP (isAPP) can
be provoked by the neurotoxic peptide Aβ. The latter decreases
in the cerebrospinal fluid of Alzheimer’s disease (AD) patients,
as a consequence of its cerebral accumulation and deposition
into senile plaques. Of similar relevance, secreted APP (sAPP)
levels can be associated with AD. The studies here presented,
reinforce the link between sAPP and Aβ and address putative
therapeutic strategies. Laminin and gelsolin are potential can-
didates; both prevent Aβ fibril formation by complexing with
Aβ, thus attenuating its neurotoxicity. We show that
preincubation of Aβ with laminin and gelsolin has the effect
of rendering it less potent to isAPP accumulation in cortical
neurons. This appears to be related to a decrease in F-actin
polymerization, whereas Aβ alone induces the polymerization.
Further, Aβ decreases gelsolin levels, and the latter is involved
in Aβ removal. Our data indicates that Aβ-laminin and Aβ-
gelsolin complexes are less neurotoxic and also less potent than
fibrillar Aβ at inducing isAPP retention. These results validate
the potential of these proteins as therapeutic strategies that
prevent the Aβ-induced effects. In hence, given that Aβ de-
creases the levels of proteins involved in its own clearance, this
may contribute to the mechanisms underlying AD pathology.
Keywords Laminin . Gelsolin . F-actin .Alzheimer’s disease
therapeutics . Fibril inhibition . Aggregation
Introduction
The deposition and accumulation of aggregates of fibrillar
Abeta (Aβ) peptides are considered one of the key processes
underlying neuronal loss in Alzheimer’s disease (AD) pathol-
ogy. The resulting senile plaques are mainly composed of Aβ
(Glenner and Wong 1984) but also include inflammatory
molecules, proteoglycans, metal ions, antioxidant proteins
and proteases, as well as clearance-related compounds
(Atwood et al. 2002). However, Aβ exists in normal brains
and cerebrospinal fluid (CSF) suggesting that it may have a
relevant physiological function. Indeed, some studies have
reported that Aβ monomers may be neuroprotective and
may support neuronal survival (Soucek et al. 2003; Brody
et al. 2008; Giuffrida et al. 2009), which is also in agreement
with the observations that many aged individuals, despite the
presence of senile plaques, show little or no cognitive decline.
Further, some authors propose that rather than be the trigger of
disease pathogenesis, Aβ may function as a protective adap-
tation to disease (Lee et al. 2004) and that its accumulation and
deposition into senile plaque may be a protective event.
Several investigators have reported that Aβ neurotoxicity
is related to the degree of fibrillization, the β-sheet structure,
and the size of the peptides (Pike et al. 1993; Lorenzo and
Yankner 1994; Dahlgren et al. 2002). The molecular mecha-
nisms responsible for the passage of normal soluble Aβ forms
to fibrils are not well understood. Nonetheless, it is known that
Aβ binds several proteins that can modulate its aggregation or
its fibrillar state thus attenuating its neurotoxicity. Among
these are laminin (Bronfman et al. 1996; Drouet et al. 1999;
Monji et al. 1999; Morgan et al. 2002) and gelsolin (Chauhan
et al. 1999, 2008; Ray et al. 2000; Qiao et al. 2005), which
have been shown to bind and form complexes with the Aβ
peptide. Laminin is a major basement membrane protein
shown to inhibit Aβ fibril formation and to disaggregate
preformed Aβ fibrils (Monji et al. 1999; Morgan and
Inestrosa 2001; Morgan et al. 2002). Gelsolin is found both
as an intracellular protein (Tanaka and Sobue 1994; Ji et al.
2008), which is able to modulate actin assembly and disas-
sembly (Janmey et al. 1985; Howard et al. 1990), and as a
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secreted plasma and CSF protein (Kwiatkowski et al. 1988;
Paunio 1994; Kulakowska et al. 2008). Like laminin, it was
reported to prevent Aβ fibrillogenesis and to defibrillize
preformed fibrils (Ray et al. 2000; Chauhan et al. 2008;
Carro 2010).
Aβ is an intracellular product of the proteolytic processing
of the Alzheimer’s amyloid precursor protein (APP) (da Cruz
e Silva and da Cruz e Silva 2003), generated by sequential
cleavage by α-secretase (mainly BACE1) (Gandy et al. 1994;
Vassar et al. 1999; Yan et al. 2001) and the γ-secretase
complex (reviewed by Kaether et al. 2006). The physiological
function of Aβ is unclear, but it is known to trigger many
cellular responses. Among the most devastating is its ability to
trigger several apoptotic and neurotoxic mechanisms and
hence to promote cellular death (Pereira et al. 2004;
Kaminsky et al. 2010). Other reports have also associated
Αβ to altered APP metabolism (Davis-Salinas et al. 1995;
Schmitt et al. 1997; Moreno-Flores et al. 1998; Carlson et al.
2000; Henriques et al. 2009a, 2010). Surprisingly, Aβ was to
modulate APP metabolism, toward the nonamyloidogenic α-
secretase pathway. In our previous work, Aβ was able to
prevent secretion of the neurotrophic and neuroprotective
secreted APP α fragment (sAPPα) (Henriques et al. 2009a)
and to decrease AICD production, consequently decreasing
APP expression levels (Henriques et al. 2009b), thus keeping
“in check” its own production. This Aβ-induced effect was
also associated with abnormalities in the cytoskeletal network
(Henriques et al. 2009a, 2010).
It seems reasonable to deduce that in AD, some of these
control events are behaving anomalously, forcing the need to
identify potential therapeutic targets. In the work presented
here, we monitored molecular relevant events: Aβ aggrega-
tion and intracellular secreted APP (isAPP) production in the
presence of gelsolin and laminin. Our data demonstrated that
inhibition of Aβ fibril formation by laminin or gelsolin was
able to partially revert Aβ-induced effects on APP metabo-
lism, decreasing is APP and reducing Aβ-induced actin poly-
merization, thus suggesting a potential therapeutic avenue for
these Aβ complexing proteins.
Materials and Methods
Laminin (from basement membrane of Engelbreth-Holm-
Swarm mouse carcinoma) and gelsolin (from bovine plasma)
were purchased from Sigma. Gelsolin was prepared as a
10 μM stock dissolved in 25 mM Tris-HCl, pH 7.5. Aβ25–35
(Sigma), Aβ1–40 and Aβ1–42 peptides (American Peptide
Company), and Aβ25–35 with a scrambled sequence (Aβscrb,
from NeoMPS) were dissolved in sterile distilled water to
obtain a 1 mM stock solution. Thioflavine T (Sigma) was
prepared as a 3 mM stock in distilled water.
The monoclonal antibody 22C11 directed against the APP
N-terminus (Boehringer) was used in this study to detect APP
and total sAPP. Holo-APP was detected using the APP C-
terminal antibody (rabbit polyclonal anti-β-APP C-terminus,
Zymed). Monoclonal anti-gelsolin antibody (Clone GS-2C4,
Sigma) was used to detect the approximately 85 KDa gelsolin
band. The monoclonal anti-β-tubulin antibody (Amersham
Pharmacia) was used as a control. Immunoreactive bands
were detected by enhanced chemiluminescence (ECL or
ECL plus for sAPP detection, Amersham Pharmacia).
Aβ Aggregation
Aβ aggregation was achieved by incubating the different
peptides for 48 h at 37 °C in phosphate-buffered saline
(PBS, pH 7.4). Prior to adding to the cells, Aβ was incubated
with laminin or gelsolin. For coincubation assays, 100 μM
Aβ25–35 was incubated in the presence of either laminin at
0.5 μM (Aβ/laminin molar ratio of 200:1) or gelsolin at
2.2 μM (Aβ/gelsolin molar ratio of 45:1) in PBS for 48 h at
37 °C, concentrations around those previously reported stud-
ies (Monji et al. 1999; Ray et al. 2000).
Fibrillar peptide and peptide complexes were then diluted
in medium, before adding to the cells in culture (see “Aβ
treatment section).
Thioflavine T (Th-T) Fluorometric Assay
Aβ25–35 fibril formation in the presence or absence of the
proteins mentioned above was monitored by a Th-T fluo-
rometric assay as described by LeVine (1993), with a few
modifications. Th-T fluorescence was measured at 0 and 48 h
of incubation at 37 °C, using a Jasco FP-777 spectrofluorom-
eter. Th-T measurements used 20 μl of incubated sample
mixed with 980 μl and 15 μM Th-T in PBS. Samples were
monitored at λEx=450 nm and 5 nM bandpass, and λEm=
482 nm and 10 nM bandpass. The background fluorescence of
Th-T and buffer alone were subtracted from the fluorescence
value obtained for each sample.
Cell Culture
Rat cortical neuronal cell cultures were prepared from embry-
onic day 18 Wistar rat fetuses as previously described
(Henriques et al. 2007). Briefly, after dissociation with trypsin
(1.0 mg/ml; 10 min; 37 °C), the cells were plated on poly-D-
lysine-coated dishes at a density of 1.0×105 cells/cm2 in B27-
supplemented Neurobasal medium (Gibco), a serum-free me-
dium combination, supplemented with glutamine (0.5 mM)
and gentamicin (60 μg/ml). Cultures were maintained in an
atmosphere of 5 % CO2 at 37 °C during 9 days before being
subjected to the various experimental conditions described.
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HeLa cells (ATTC CRM-CCL-2) were grown in
Dulbecco’s Modified Eagle Medium (DMEM), supplemented
with 10% fetal bovine serum, 1 % antibiotic-antimycotic, and
NaHCO3 at 3.7 g/l.
Aβ Treatment
Exposure of cells to Aβ was preceded by an aggregation
step and the effect of different Aβ peptides and concentrations
was evaluated (Fig. 1). Subsequent experiments were carried
out by preincubating Aβ25–35 peptide alone or in the presence
of the different proteins (laminin and gelsolin) during 48 h at
37 °C; 100 μl of each preparation were then diluted in 900 μl
of the complete corresponding medium and added to the cells
for a 24 h period. Under these conditions, Aβ was used at a
final concentration of 10 μM, laminin at 50 nM, and gelsolin
at 220 nM.
To evaluate gelsolin levels, HeLa cells were treated with
10 μM of aggregated Aβ25–35 and Aβ1–42 for 24 h in a
DMEM serum-free combination.
Monitoring Apoptosis
In order to morphologically evaluate apoptosis, cells were
plated at a density of 0.8×105 cells/cm2 on poly-D-lysine-
coated coverslips. After the appropriate treatments, cells were
fixed with 4 % paraformaldehyde diluted in media (1:1) for
2 min and then incubated for 15 min in undiluted paraformal-
dehyde. Following three washes with PBS, cells were incu-
bated with Hoechst dye 33258 (5 mg/ml stock, Sigma) at
5 μg/ml in PBS for 3 min to allow for nuclear staining. For
quantitative analysis of apoptosis, cell nuclei were visualized
using a 4′,6-diamidino-2-phenylindole (DAPI) filter in an
Olympus IX-81 inverted epifluorescence microscope. To
evaluate the percentage of apoptotic cells, ten independent
fields were analyzed (approximately 400 cells) per experimen-
tal condition. Under control conditions, primary neuronal
cultures exhibited approximately 10 % of apoptotic cells.
F-actin Labeling
Subsequent to the different experimental conditions, HeLa
cells were fixed with paraformaldehyde and permeabilized
with a cold solution of acetone (−20 °C) for 3 min. Cells were
then washed with PBS and subsequently incubated with PBS
containing 1 % bovine serum albumin (BSA) for 1 h. This
blocking solution was removed, and phallotoxin staining so-
lution (labels F-actin) was added to the cells (1.5 U/100 lL in
PBS containing 1 % BSA) for 20 min at 25 °C. After PBS
washing, the coverslips were mounted on microscope glass
slides using antifading reagents containing DAPI for nucleic
acids (Vectashield, Vector Laboratories, Burlingame, CA). To
evaluate the effects on F-actin polymerization, 15 independent
fields (approximately 60 cells) were analyzed per experimen-
tal condition of independent experiments. Epifluorescence
images were acquired with an Olympus IX-81 motorized
inverted epifluorescence microscope equippedwith the appro-
priate filter combinations and a 100× objective (Plan-
Neofluar, 100×/1.35 oil objective). Photographs were ac-
quired with a Digital CCD monochrome camera F-View II
(Soft Imaging System) and processed with the AnalySIS
software (Soft Imaging System) (Vieira et al. 2009).
Sample Collection and Protein Analysis
Following appropriate treatments, conditioned media and
cells were collected into boiling 1 % sodium dodecyl sulfate
(SDS). The cell lysates were homogenized as previously
described (Amador et al. 2004). Protein determination of the
lysates was carried out with the BCA kit (Pierce). Samples
were normalized for protein content; 50 μg of each lysate was
loaded and separated on a 7.5 or 5–20% gradient (for gelsolin
experiments) SDS-PAGE and then electrophoretically trans-
ferred onto a nitrocellulose membrane. Immunoblotting was
carried out with the C-terminal antibody for holo-APP (hAPP)
detection or the 22C11 antibody, which detects hAPP and
isAPP (intracellular sAPP). Anti-gelsolin and anti-β-tubulin
antibodies for detecting gelsolin and tubulin, respectively,
were also used. Medium-secreted/extracellular sAPP
(esAPP) was detected by subjecting the conditioned medium
to Western blot analysis and using the 22C11 antibody.
Detection was achieved using ECL (for hAPP, gelsolin, and
tubulin) or ECL plus (for sAPP) detection systems.
Quantification and Statistical Analysis
Quantity One densitometry software (Bio-Rad) was used to
scan and quantify immunoblot band intensity. Data are
expressed as mean±SEM of at least three independent exper-
iments. Statistical analysis was carried out using one-way
analysis of variance (ANOVA). When the F values were
significant, the Tukey test was applied to compare all pairs
of groups. For gelsolin experiments, one sample t test analysis
was performed. Statistical differences have been determined at
P<0.05.
Results and Discussion
Laminin and Gelsolin Effects on Aβ25–35 Aggregation
and Neurotoxicity
Aβ toxicity is closely associated with its fibril state; hence,
proteins which can modulate the latter may potentially prevent
Aβ amyloidogenic responses. Previous reports showed that
laminin (Drouet et al. 1999; Monji et al. 1999; Morgan et al.
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2002) and gelsolin (Ray et al. 2000; Qiao et al. 2005) inhibit
fibril formation or depolymerize preformed fibrils of both
Aβ1–40 and Aβ1–42 peptides. The effects of both these pro-
teins on Aβ25–35 aggregation and subsequent effects on APP
metabolism were evaluated in this study.
To quantify the extent to which Aβ25–35 aggregates, the
Th-T fluorescence assay was used. Although Aβ25–35 spon-
taneously aggregates in solution, an additional aggregation
period of 48 h at 37 °C resulted in an increase of the relative
Th-T fluorescence intensity (Fig. 1a) from 12 to 22 fluores-
cence units. The procedure was repeated, but in the presence
of laminin and gelsolin in a molar ratio of 200:1 for Aβ and
laminin and 45:1 for Aβ and gelsolin, concentrations chosen
were near those previously employed (Monji et al. 1999; Ray
et al. 2000). By comparing with the incubation of Aβ alone, a
significant decrease in the fluorescence of Th-Twas obtained
when Aβ25–35 was coincubated with laminin or gelsolin for
48 h (from 22 fluorescence units to 4 and 3, respectively).
Hence, as expected in the presence of these two proteins,
Aβ25–35 fibril formation was dramatically inhibited (Fig. 1a).
Data also indicate that both laminin and gelsolin bind Aβ
within the Aβ25–35 region.
Laminin and gelsolin inhibition of fibril formation have
been associated with a decrease in Aβ-induced neurotoxicity
(Morgan et al. 2002; Qiao et al. 2005; Carro 2010). Like the
full-length Aβ peptides, Aβ25–35 was previously reported to
induce apoptosis, thus neurotoxicity of Aβ and Aβ-
complexes was evaluated, by quantitative analysis of cell
nuclei following Hoechst staining. The percentage of
picnotic/apoptotic cell nuclei was estimated, for primary cor-
tical cultures when exposed to 10 μM of Aβ25–35, both in the
absence and presence of laminin (50 nM) or gelsolin (220 nM)
for 24 h (Fig. 1b). The levels of apoptosis induced by Aβ
peptide alone were low (∼15% above control levels). Of note,
the levels could be decreased to ∼5 % above control levels, if
Aβ was preincubated with either laminin or gelsolin. Thus,
indicating that laminin and gelsolin can significantly attenuate
the toxic effects of Aβ25–35 as deduced from the decrease in
Aβ-induced apoptosis.
Effect of Aβ-Laminin and Aβ-Gelsolin Complexes on APP
Metabolism
As discussed above, the Aβ binding proteins (laminin and
gelsolin) prevent fibrillogenesis rendering Aβ less neurotoxic.
Consequently, we took advantage of this effect, to evaluate
whether Aβ-induced abnormal APP processing could also
fluctuate in response to the aggregation state of the former.
Hence, the Aβ protein complexes were added to cultured
cells, and APP metabolism was evaluated. When primary
cortical cultures were treated with 10 μM of aggregated
Aβ25–35 for 24 h, an approximately fourfold increase in intra-
cellular sAPP (isAPP) levels was observed (Fig. 2a) as detect-
ed by using the N-terminal APP 22C11 antibody. This anti-
body detects both sAPP and hAPP, but since hAPP levels did
not change in response to Aβ (C-terminal detection, Fig. 2a),
the observed increase was due to isAPP accumulation. This
was previously shown by our group for non previously aggre-
gated Aβ. Regarding the naturally produced Aβ peptides, at
20 μM concentration, Aβ1–40 peptide was much less effective
at inducing an increase in isAPP than Aβ25–35 and Aβ1–42
peptides. Consistent with the previous observations, medium-
secreted extracellular sAPP (esAPP) decreased upon exposure
to Aβ, once again with the exception of Aβ1–40 (20 μM). This
data is in agreement with a decrease propensity to aggregate
and a less toxic effect of the Aβ1–40 peptide when compared
with the Aβ1–42. This peptide species and concentration-
dependent effect were mirrored in the increase in isAPP
retention (Fig. 2a). The scramble Aβ25–35 peptide was used
as a control and, in fact, confirmed the specificity of the Aβ
response.
However, in the presence of Aβ-laminin and Aβ-gelsolin
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Fig. 1 Effect of laminin and gelsolin on Aβ aggregation and toxicity. a
Aβ25–35 was incubated at 37 °C for 48 h, either alone or in the presence of
0.5 μM laminin (Lam) or 2.2 μM gelsolin (Gel), and the fluorescence
intensity of Th-T was measured at λex=450 nm and λem=482 nm.
Results are expressed as mean±SEM of at least three independent exper-
iments. ##P<0.01, significantly different from Aβ 48 h; *P<0.05 signif-
icantly different between 0 and 48 h Aβ treatment, Tukey post hoc test. b
Aβ25–35 apoptotic induction in the presence of laminin and gelsolin was
determined usingHoechst stain. Cortical neurons were visualized, and the
percentage of apoptotic nuclei for each condition was determined relative
to control. C control, Lam laminin, Gel gelsolin. ##P<0.01, significantly
different from Aβ; ***P<0.001, significantly different from control;
Tukey post hoc test
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fold, respectively, when compared with Aβ treatment alone
(Fig. 2b). Thus, by decreasing Aβ fibrillogenesis with both
laminin and gelsolin, one promotes less toxic Aβ species,
resulting in a decrease in Aβ-induced isAPP accumulation.
Laminin and gelsolin alone showed no effect on APP intra-
cellular levels (Fig. 2b).
With respect to medium-secreted APP (esAPP), we ob-
served that aggregated Aβ25–35 resulted in decreased total
esAPP levels. For the proteins tested, it would be expected
that diminishing isAPP would result in increased esAPP se-
cretion. This was evident for laminin, which induced a slight
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Fig. 2 Aβ-laminin and Aβ-gelsolin complexes revert Aβ-induced
anomalies in neuronal APP processing. a Aβ25–35, Aβ1–40, and Aβ1–42
were aggregated for 48 h at 37 °C. Following aggregation, peptides were
added to primary neuronal cultures at different concentrations for 24 h.
Scramble 25–35 peptide was used as a control (Scrb). b Primary cortical
cultures were incubated for 24 h with 10 μM Aβ in the absence or
presence of laminin (Lam) or gelsolin (Gel). Intracellular holo-APP
(hAPP) protein was detected by subjecting the cellular lysates to Western
blot analysis with the C-terminal antibody. The levels of intracellular
hAPP and sAPP (isAPP) and extracellular (medium secreted) sAPP
(esAPP) were detected using the N-terminal antibody 22C11. Left-
pointing pointer, isAPP retention, corresponds to protein bands
immunoreactively positive for 22C11 but negative for C-terminal anti-
body. Quantitative results are expressed as mean±SEM of three indepen-
dent experiments. Fold increase in isAPP and esAPP; #P<0.01 and
###P<0.01, significantly different from Aβ; *P<0.05, **P<0.01, and







Fig. 3 Aβ-laminin and Aβ-
gelsolin complexes on F-actin
polymerization. Upon incubation
for 24 h with either Aβ25–35 or
Aβ1–42, HeLa cells were stained
with Alexa Fluor 568 conjugated
phallotoxin solution (labeled fila-
mentous actin, F-actin). Images
were acquired using an Olympus
IX-81 microscope. C control,
Lam laminin, Gel gelsolin. Bar,
10 μm
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the effect of Aβ alone. Laminin was previously shown to
decrease sAPP secretion and to affect intracellular APP bio-
genesis and catabolism (Monning et al. 1995; Bronfman et al.
1996). Therefore, we would not expect a complete reversion
of the sAPP secretion. The reversion on sAPP secretion was
not significant with Aβ-gelsolin complexes. This may reflect
different modes of action for laminin and gelsolin or simply
that the Aβ-protein ratios used were not sufficient to revert the
Aβ-induced effects. Overall, under the conditions tested, the
Aβ effects on APP processing were reversed or attenuated,
with respect to isAPP accumulation for gelsolin and laminin,
and the latter also partially reverted the decrease in esAPP,
which is a typical response following Aβ exposure.
F-actin Polymerization upon Aβ-laminin and Aβ-gelsolin
Complexes
Aβ effects on isAPP retention were previously correlated with
abnormalities in the cytoskeletal network, in particular in both
actin and tubulin networks, since both actin depolymerization
and microtubule stabilization agents could partially revert the
Aβ-induced isAPP retention (Henriques et al. 2010). In the
present study, we evaluate the F-actin polymerization in the
presence and absence of Aβ-laminin and Aβ-gelsolin com-
plexes (Fig. 3). Under control conditions, we could observe
actin fibers, but these are much shorter and thinner when
compared with conditions in the presence of Aβ peptide. In
fact, Aβ exposure led to an increase in F-actin polymerization
and in the thickness of the actin stress fibers formed.
Monomeric G-actin is in dynamic equilibrium with polymer-
ized F-actin. Gelsolin is an actin-capping protein, which may
regulate actin polymerization by binding at the plus ends,
therefore preventing elongation. However, rapid signal cas-
cades can induce actin polymerization and reverse the entire
process. F-actin filaments tend to be slightly decreased below
the plasma membrane, in particular for laminin treatment
comparative to control, which may be correlated with a slight
decrease in sAPP secretion for those proteins (Fig. 2b). The
data suggest that a basal level of F-actin polymerization is
needed for sAPP secretion, otherwise, an enormous increase
in sAPP secretion should be expected under actin depolymer-
ization conditions. In agreement, previous data from our group
showed that incubation with an actin-depolymerizing agent
only partially reverse the inhibition of sAPP secretion induced
by Aβ (Henriques et al. 2010).
Aβ-laminin and Aβ-gelsolin complexes result in de-
creased F-actin polymerized filaments (Fig. 3) when com-
pared with Aβ conditions. The cytoskeletal alterations in-
duced by Aβ could be partially reverted by both Aβ-laminin
and Aβ-gelsolin complexes. Intracellular sAPP retention de-
creased in both cases, but contrary to what was expected, only
Aβ-laminin complexes result in a slight increase of esAPP
(Fig. 2b). This may correlate with the individual effects of the
proteins alone in F-actin remodelling/dynamics, which
can render in decreased esAPP. Presently, it is difficult to
interpret the significance of the decrease in isAPP levels
toward control conditions, induced by these Aβ-protein com-
plexes, because the metabolism and clearance mechanisms of
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Fig. 4 Gelsolin levels in response to Aβ. HeLa cells were incubated for
24 h with Aβ25–35 and Aβ1–42, both at 10 μM and aggregated. a
Intracellular gelsolin levels were monitored by Western blot analysis
using anti-gelsolin antibody. Tubulin was used as an internal control. b
Quantitative results are expressed as a fold increase relative to the basal
levels. C control. *P<0.05 and **P<0.01, significantly different from













Fig. 5 Schematic representation of the Aβ-disaggregating proteins’
mode of action. Aggregated Aβ induces neurotoxicity, altered APP
processing and cytoskeletal rearrangements, which can be reversed by
laminin and gelsolin. These proteins are able to inhibit Aβ fibril forma-
tion and aggregation or to defibrillize its preformed fibrils, thus
preventing Aβ-mediated effects
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Nonetheless, we postulate that the laminin- or gelsolin-Aβ
complexes formed may inhibit Aβ-mediated signaling and/or
be intracellularly targeted for degradation, therefore
preventing Aβ-induced responses. Of note, the sAPP frag-
ment resulting from the nonamyloidogenic pathway was re-
ported to have neurotrophic and neuroprotective properties
(Mattson et al. 1993; Meziane et al. 1998); hence, isAPP
accumulation may contribute to neuronal degeneration.
Therefore, modulation of sAPP intracellular accumulation
and secretion may thus be a protective event.
Aβ Effects on Gelsolin Levels
Due to their depolymerization properties and their capacity to
bind Aβ, both laminin and gelsolin could potentially alter the
Aβ periphery; brain load, by promoting the reduction of this
toxic peptide in the brain. In particular, peripheral administra-
tion of plasma gelsolin resulted in a reduction of Aβ1–40/Aβ1–
42 and Aβ load in the brains of APP/PS transgenic mice that
exhibited elevated intraneuronal Aβ1–42 levels (Matsuoka
et al. 2003). Moreover, in similar transgenic mouse models
of AD, peripheral delivery of plasmid DNA encoding plasma
gelsolin, also led to a reduction of Aβ levels in the brain
(Hirko et al. 2007). The reduction in Aβ pathology appeared
to be related to an increase in activated and reactive microglia
and to soluble oligomeric forms. Also, it has been previously
reported that plasma gelsolin levels were decreased in AD
patients (Guntert et al. 2010). Herein, we show that both
Aβ25–35 and Aβ1–42 can decrease the levels of this Aβ-
disaggregating protein (Fig. 4). Hence, the Aβ clearance
mechanisms prompted by gelsolin may be dysregulated by
the Aβ peptide itself, which can contribute to its own deposi-
tion and accumulation in AD brains. Hence, Aβ-
disaggregating proteins can be relevant in the development
of future therapeutic strategies designed to act at the level of
Aβ aggregation and accumulation.
Overall, this study showed that both laminin and gelsolin
were able to revert Aβ effects not only at the neurotoxic level
but also at the metabolic level. Besides reverting isAPP levels,
laminin could also increase esAPP secretion, which may
counteract the Aβ-induced neurotoxic effects. This response
could be related to a decrease in F-actin polymerization, which
could also be induced by Aβ-disaggregating protein com-
plexes. At the molecular level, by preventing Aβ aggregation,
these proteins may exert their effect at several distinct stages
(Fig. 5), namely, by interfering with Aβ-induced cytoskeletal
alterations and isAPP retention. Of note, gelsolin was reported
to be involved in Aβ clearance in the brain. Since we show
that the latter peptide was able to decrease gelsolin levels, this
may represent a pathway by which Aβ may contribute to its
own brain accumulation. Although the molecular events un-
derlying the mode of action of both proteins are unknown, our
data suggest that both Aβ-disaggregating proteins may be of
therapeutic value for AD pathology.
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